

IGI LABORATORIES, INC  
Form 8-K  
May 21, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 20, 2015**

**IGI LABORATORIES, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware                      001-08568                      01-0355758  
(State or other jurisdiction) (Commission File Number) (IRS Employer)**

of incorporation)

Identification No.)

105 Lincoln Avenue  
Buena, New Jersey 08310  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (856) 697-1441

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year**

On May 20, 2015, at the 2015 Annual Meeting of Stockholders (the “**Annual Meeting**”) of IGI Laboratories, Inc. (the “**Company**”), the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “**Charter**”), to be effective May 20, 2015, to increase the number of authorized shares of our common stock to 100,000,000 shares.

The amendment to the Charter is filed as Exhibit 3.1 to this report and is incorporated by reference herein. The foregoing summary of the amendment is qualified in its entirety by reference to the full text of the Charter, as amended.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

(a) On May 20, 2015, the Company held the Annual Meeting. At the Annual Meeting, the holders of 46,711,955 shares of the Company’s common stock were present in person or represented by proxy, which represents 88.36% of the total shares of outstanding common stock entitled to vote as of the record date of April 27, 2015.

(b) The following actions were taken in the Annual Meeting:

The following six nominees were reelected to serve on the Company’s Board of Directors (the “**Board**”) until the (1) Company’s 2016 annual meeting of stockholders or until their respective successors have been elected and qualified, or until their earlier resignation or removal:

<u>Name of Director Nominees</u>	<u>Votes For</u>	<u>Votes Withheld</u>	<u>Broker Non-Vote</u>
Jason Grenfell-Gardner	35,664,493	388,969	10,658,493
Narendra N. Borkar	35,647,458	406,004	10,658,493
Bhaskar Chaudhuri	35,009,646	1,043,816	10,658,493
Steven Koehler	35,673,855	379,607	10,658,493
James C. Gale	35,002,685	1,050,777	10,658,493
John Celentano	35,654,143	399,319	10,658,493

(2) The amendment to the Company’s Charter to increase the number of authorized shares of our common stock to 100,000,000 shares, was approved, based on the following votes:

**Votes For Votes Against Votes Abstain Broker Non-Vote**

35,828,814 165,553 59,095 10,658,493

(3) The issuance of the Company's common stock upon conversion of our 3.75% convertible senior notes due 2019 was approved, based on the following votes:

**Votes For Votes Against Votes Abstain Broker Non-Vote**

35,322,389 423,327 307,746 10,658,493

(4) The selection of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015, was ratified, based on the following votes:

**Votes For Votes Against Votes Abstain Broker Non-Vote**

46,381,527 275,195 55,233 0

(5) The compensation of the Company's named executive officers, as disclosed in our proxy statement, was approved by an advisory vote, based on the following votes:

**Votes For Votes Against Votes Abstain Broker Non-Vote**

33,717,575 2,019,466 316,421 10,658,493

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

**Number Description**

3.1 IGI Laboratories, Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IGI LABORATORIES,  
INC.**

Date: May 20, 2015 By: /s/ Jenniffer Collins  
Name: Jenniffer Collins  
Title: Chief Financial Officer